Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formulation Optimization of Avenciguat in Healthy Males
NCT04926246Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of avenciguat in systemic sclerosis (SSc), diabetic kidney disease (DKD) and Liver cirrhosis (LC) (13 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve from 0 extrapolated to infinity up to 5 days. Started Jul 2021; status: completed.
02
Drugs
avenciguat
03
Conditions
systemic sclerosis (SSc)diabetic kidney disease (DKD)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT04926246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926246.